TABLE 2.

TEAEs in MAD panels reported in greater than one participant treated with milvexian

AE, n (%)	Pooled placebo (n = 14)	Panel 7 milvexian 5 mg q.d. fasted (n = 6)	Panel 8 milvexian 20 mg q.d. fasted (n = 6)	Panel 9 milvexian 70 mg q.d. fasted (n = 6)	Panel 12 milvexian 35 mg b.i.d. fasted (n = 6)	Panel 10 milvexian 200 mg q.d. fasted (n = 6)	Panel 13 milvexian 200 mg b.i.d. fasted (n = 6)	Panel 11 milvexian 500 mg q.d. fed (n = 6)	All participants treated with milvexian (N = 42)
Any TEAE	8 (57.1)	4 (66.7)	1 (16.7)	5 (83.3)	2 (33.3)	4 (66.7)	2 (33.3)	3 (50.0)	21 (50.0)
Headache	1 (7.1)	2 (33.3)	1 (16.7)	2 (33.3)	0	1 (16.7)	0	0	6 (14.3)
Diarrhea	3 (21.4)	1 (16.7)	0	3 (50.0)	0	1 (16.7)	0	0	5 (11.9)
Dizziness	1 (7.1)	0	0	1 (16.7)	1 (16.7)	0	1 (16.7)	0	3 (7.1)
Nausea	1 (7.1)	0	0	1 (16.7)	0	2 (33.3)	0	0	3 (7.1)
Abdominal discomfort	0	1 (16.7)	0	1 (16.7)	0	0	0	0	2 (4.8)
Abdominal pain	1 (7.1)	0	0	1 (16.7)	0	1 (16.7)	0	0	2 (4.8)
Oropharyngeal pain	0	0	0	0	0	1 (16.7)	1 (16.7)	0	2 (4.8)
Pain in extremity	0	0	0	1 (16.7)	0	1 (16.7)	0	0	2 (4.8)

Abbreviations: AE, adverse event; MAD, multiple ascending dose; TEAE, treatment‐emergent adverse event.